Cantor Fitzgerald Notes IPR&D Charge Impact on Abbvie's (ABBV) 3Q EPS
Tweet Send to a Friend
Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $250.00 price target on Abbvie (NYSE: ABBV).The analyst commented, "we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
